Max-planck-gesellschaft Zur F&#xf6;rderung Der Wissenschaften E. V.

Universitatsklinikum Hamburg-eppendorf

Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts

Zytovision Gmbh

Guido Sauter

Hans Lehrach

Michal Schweiger

Khawla Al-Kuraya

Holger Sueltmann

Frederik Holst

Thorsten Schlomm

Christian Ruiz

Stefan Boerno

Ronald Simon

Phillip Stahl

Holger Sültmann

Stefan Börno

Philip Stahl

The invention relates to the identification and selection of novel genomic regions (biomarker) and the identification and selection of novel genomic region combinations which are hypermethylated in subjects with prostate cancer compared to subjects without prostate cancer. Nucleic acids which selectively hybridize to the genomic regions and products thereof are also encompassed within the scope of the invention as are compositions and kits containing said nucleic acids and nucleic acids for use in diagnosing prostate cancer. Further encompassed by the invention is the use of nucleic acids which selectively hybridize to one of the genomic regions or products thereof to monitor disease regression in a patient and the efficacy of therapeutic regimens.

Prostate cancer markers

The present invention relates to an in-vitro method of identifying a tumor resulting from a proliferative breast disease as responsive to anti-estrogen treatment. Further, the invention relates to an in-vitro method of identifying a candidate patient with a proliferative breast disease as suitable for anti-estrogen treatment. In a further aspect, the invention provides an in-vitro method of identifying an individual with a non-cancerous proliferative breast disease who is at risk of developing breast cancer. The invention also provides kits for performing the above methods.

Detection of ESR1 amplification in breast cancer

Growing community of inventors

Hamburg, Germany

Guido Sauter